Zalicus Inc Com (NASDAQ:ZLCS)

CAPS Rating: 3 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

Recs

2
Player Avatar pchop123 (76.54) Submitted: 7/18/2012 10:22:35 AM : Outperform Start Price: $1.04 ZLCS Score: +8.80

Still has the likely potential to get UP and really Run UP

Featured Broker Partners


Advertisement